Stephan M. Fellerwas trained in Biology and conducted his diploma research at the University of Heidelberg, Germany, working on the heart hormone ANP. He then moved to The Rockefeller University, New York City, NY, USA, for his PhD research in Cell Biology and Biochemistry (degree awarded in 1994) where he studied (proto-)oncogenes and protein-protein interactions. Returning to Germany in 1995, after a year of postdoc at Rockefeller, he started his own independent junior research group in the same research area at the University of Würzburg, Germany, before moving his laboratory in 2001 to the Sir David Weatherall Institute of Molecular Medicine in Oxford, UK as a principal investigator, Oxford University faculty member and from 2009 as a member of senior common room at Corpus Christi College. In 2013, he joined the Medical Faculty of the MLU as Professor of Tumor Biology. His current research interests include the dynamic architectures and roles of IDPs in signaling pathway cross-talk as well as cancer drug combination therapy. He is also an advocate for preventive medicine and academic international exchange.
Projects within the RTG
Upper panel: Project with Milton T. Stubbs
Lower Panel: Project with Mirko Buchholz
Bongartz H, Hessenkemper W, Müller C, Fensky M, Fritsch J, Mandel K, Behrmann I, Haan C, Fischer T, Feller SM, Schaper F. The multi-site docking protein Gab1 is constitutively phosphorylated independent from recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukemia cells. Cell Signal 2017, 35, 37-47.
Wu Z, Doondeea JB, Gholami AM, Janning MC, Lemeer S, Kramer K, Eccles SA, Gollin SM, Grenman R, Walch A, Feller SM, Kuster B. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol. Cell Proteomics. 2011, 10: M111.011635.*
Simister PC, Schaper F, O’Reilly N, McGowan S, Feller SM. Self-organization and regulation of intrinsically disordered proteins with folded N-termini. PLoS Biol. 2011, 9: e1000591.